Universal Beteiligungs und Servicegesellschaft mbH Has $16.16 Million Stock Holdings in Crinetics Pharmaceuticals, Inc. $CRNX

Universal Beteiligungs und Servicegesellschaft mbH increased its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) by 13.5% in the 3rd quarter, Holdings Channel reports. The fund owned 387,925 shares of the company’s stock after purchasing an additional 46,220 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Crinetics Pharmaceuticals were worth $16,157,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of CRNX. Farther Finance Advisors LLC increased its holdings in shares of Crinetics Pharmaceuticals by 523.7% in the 3rd quarter. Farther Finance Advisors LLC now owns 842 shares of the company’s stock valued at $35,000 after purchasing an additional 707 shares during the period. Headlands Technologies LLC purchased a new position in Crinetics Pharmaceuticals during the second quarter valued at approximately $30,000. Raymond James Financial Inc. purchased a new position in Crinetics Pharmaceuticals during the second quarter valued at approximately $45,000. Penserra Capital Management LLC acquired a new position in Crinetics Pharmaceuticals in the 2nd quarter valued at approximately $48,000. Finally, Osaic Holdings Inc. lifted its position in Crinetics Pharmaceuticals by 126.1% in the 2nd quarter. Osaic Holdings Inc. now owns 2,478 shares of the company’s stock worth $75,000 after buying an additional 1,382 shares in the last quarter. 98.51% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Crinetics Pharmaceuticals

In other Crinetics Pharmaceuticals news, insider Isabel Kalofonos sold 2,500 shares of the business’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $55.00, for a total transaction of $137,500.00. Following the completion of the transaction, the insider owned 834 shares of the company’s stock, valued at $45,870. The trade was a 74.99% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Dana Pizzuti sold 5,000 shares of the company’s stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $42.66, for a total transaction of $213,300.00. Following the sale, the insider owned 66,270 shares of the company’s stock, valued at $2,827,078.20. This trade represents a 7.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 4.60% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Leerink Partners boosted their price target on shares of Crinetics Pharmaceuticals from $80.00 to $88.00 and gave the company an “outperform” rating in a report on Monday, September 29th. Oppenheimer boosted their target price on Crinetics Pharmaceuticals from $73.00 to $87.00 and gave the company an “outperform” rating in a research note on Tuesday, September 30th. Citizens Jmp cut their price target on Crinetics Pharmaceuticals from $108.00 to $105.00 and set a “market outperform” rating for the company in a research note on Thursday, January 8th. Robert W. Baird boosted their price target on Crinetics Pharmaceuticals from $58.00 to $62.00 and gave the company an “outperform” rating in a research note on Friday, September 26th. Finally, The Goldman Sachs Group raised shares of Crinetics Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $67.00 price objective on the stock in a research report on Monday, January 12th. Eleven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $82.50.

Crinetics Pharmaceuticals Stock Performance

Shares of CRNX stock opened at $53.18 on Friday. The stock’s 50 day simple moving average is $48.76 and its 200 day simple moving average is $40.30. Crinetics Pharmaceuticals, Inc. has a twelve month low of $24.10 and a twelve month high of $57.99. The company has a market capitalization of $5.05 billion, a price-to-earnings ratio of -11.74 and a beta of 0.20.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last announced its earnings results on Thursday, November 6th. The company reported ($1.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.11). The business had revenue of $0.14 million during the quarter, compared to analysts’ expectations of $0.39 million. During the same period in the prior year, the firm earned ($0.96) earnings per share. On average, analysts forecast that Crinetics Pharmaceuticals, Inc. will post -3.73 EPS for the current fiscal year.

Crinetics Pharmaceuticals Company Profile

Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company’s proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics’ research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.

The company’s lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.